Hyperfine Announces Alzheimer’s Research with Swoop System Data

Hyperfine presented additional research data and images using its Swoop system, an FDA-cleared portable magnetic resonance (MR) imaging system to image patients with Alzheimer’s disease who are part of the observational, investigator-initiated CARE PMR study. 

The CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study collected data from multiple sites assessing the clinical utility and workflow benefits of using Swoop system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy.

The Swoop system helps to detect amyloid-related imaging abnormalities (ARIA-E) when monitoring Alzheimer’s patients receiving amyloid-targeting therapy. 

New research from Washington University in St. Louis was presented at CTAD. The study was performed at a leading center in Alzheimer’s disease research using ultra-low-field MR imaging with the Swoop system and an actively enrolling center in the CARE PMR study. 

The presentation showcased multiple cases comparing images obtained with the ultra-low-field Swoop portable MR brain imaging system with images from a high-field 3 tesla MRI scanner. The Swoop system images, processed using the latest advancements in AI-driven research software, demonstrated impressive image quality that shows promise for use in assisting physicians in detecting ARIA-E.

Other recent presentations at significant Alzheimer’s meetings, including the Alzheimer’s Association International Conference (AAIC) in Philadelphia, AAIC in Tokyo, and the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, have showcased the potential value of the Swoop system in Alzheimer’s patient management.

Dr. Edmond Knopp, Chief Medical Officer at Hyperfine, stated, “I want to congratulate Washington University for their leadership in Alzheimer’s research, particularly with the use of portable MR brain imaging. The impressive image quality achievable with our ultra-low-field MRI technology opens up the potential to enable the ability to provide critical diagnostic information for patients with Alzheimer’s disease across many sites of professional care, including infusion centers and clinics that currently cannot offer on-site imaging capabilities. These presentations provide early evidence that portable MRI could transform Alzheimer’s disease management.”